Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)
Public ClinicalTrials.gov record NCT03222973. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS. The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.
Study identification
- NCT ID
- NCT03222973
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 263 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 58 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2017 (Actual)
- Primary completion
- Feb 12, 2021 (Actual)
- Completion
- Feb 12, 2021 (Actual)
- Last update posted
- Apr 28, 2022
2017 – 2021
United States locations
- U.S. sites
- 51
- U.S. states
- 28
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Cullman | Alabama | 35058 | — |
| Research Site | Gilbert | Arizona | 85234 | — |
| Research Site | Berkeley | California | 94705 | — |
| Research Site | Long Beach | California | 90806 | — |
| Research Site | Newport Beach | California | 92663 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Centennial | Colorado | 80112 | — |
| Research Site | Fort Collins | Colorado | 80528 | — |
| Research Site | Stamford | Connecticut | 06905 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Sunrise | Florida | 33351 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30309 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Overland Park | Kansas | 66212 | — |
| Research Site | Lexington | Kentucky | 40513 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Lexington | Massachusetts | 01805 | — |
| Research Site | Wellesley | Massachusetts | 02481 | — |
| Research Site | Farmington Hills | Michigan | 48334 | — |
| Research Site | Minneapolis | Minnesota | 55422 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | St Louis | Missouri | 63131 | — |
| Research Site | Las Vegas | Nevada | 89106 | — |
| Research Site | Freehold | New Jersey | 07728 | — |
| Research Site | Teaneck | New Jersey | 07666 | — |
| Research Site | Latham | New York | 12110 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Columbus | Ohio | 43214 | — |
| Research Site | Dayton | Ohio | 45417 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Portland | Oregon | 97225 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Willow Grove | Pennsylvania | 19090 | — |
| Research Site | Knoxville | Tennessee | 37922 | — |
| Research Site | Memphis | Tennessee | 38018 | — |
| Research Site | Dallas | Texas | 75390-8806 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | Orem | Utah | 84058 | — |
| Research Site | Salt Lake City | Utah | 84103 | — |
| Research Site | Seattle | Washington | 98122 | — |
| Research Site | Seattle | Washington | 98133 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03222973, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03222973 live on ClinicalTrials.gov.